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Abstract
The group of new oral anticoagulants or NOACs, now termed direct oral anticoagulants or DOACs, with their
favourable results from large scale phase III clinical trials, represent a major advancement and expanded
armamentarium in antithrombotic therapy. Dabigatran, rivaroxaban, apixaban and edoxaban are now in clinical
routine use for prevention and treatment of arterial and venous thrombotic diseases as addressed in their clinical
trials. Usage of the DOACs is expected to increase as clinicians gain more experience and reassurance with data
from the real world studies which are generally consistent with that from clinical trials. Development of specific
antidotes in management of bleeding complications and development of coagulation assays for their plasma levels
will further boost the confidence in the DOACs. Nonetheless, there are still limitations associated with the DOACs.
Many patients in need of anticoagulant therapy for indications not studied in the clinical trials will not be eligible
for treatment with a DOAC. Conditions where more data is required include DOACs use in the paediatric age
group, patients with atrial fibrillation and valvular heart disease, thrombosis associated with the anti-phospholipid
syndrome and cancer associated thrombosis. The affordability and access to these drugs may pose an issue for
many patients under healthcare systems not providing for these medications. With four new anticoagulants coming
onboard very quickly, the focus has shifted to the practical approach and management in real life as many
clinicians are not yet familiar with the DOACs. Clinicians need to be educated on how to manage this new class for
drugs, from choosing the appropriate drug to prevention and managing bleeding complications as a lack of
knowledge and understanding in these drugs will lead to inappropriate use and compromise on patient safety.
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Background
Oral anticoagulation is essential for treatment of arterial
and venous thromboembolic diseases. Vitamin K antago-
nists such as warfarin and Coumadin were the only oral
anticoagulant available for decades until the introduction
of a group of new and novel oral anticoagulants, initially
coined as NOACs. Their favourable pharmacological prop-
erties and convenient administration overcome many of
the problems associated with the vitamin K antagonists
such as frequent coagulation blood tests, dose adjustments
and perceived dietary restrictions. In addition, the NOACs,
as a class have been shown to have significantly less intra-
cranial haemorrhage (ICH) than warfarin, thus mitigating
the most feared complication of anticoagulation treatment.
Subsequently, the term DOACs or ‘direct oral anticoagu-
lants” was preferred to refer this class of oral anticoagu-
lants with similar pharmacological properties that directly
inhibit a single target [1]. Currently, four DOACs, namely
Dabigatran, Rivaroxaban, Apixaban and Edoxaban are reg-
istered for use in prevention of stroke and systemic embol-
ism in atrial fibrillation (AF), venous thromboembolism
(VTE) prophylaxis in major orthopaedic surgery, treat-
ment of acute VTE and prevention of recurrent VTE. In
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addition, Rivroxaban is also registered for use in prevention
of cardiovascular deaths after acute coronary syndrome.
With the DOACs becoming commercially available and
more widely used, the focus has shifted to their practical
use in real life. The purpose of this article is to highlight
available phase IV or post marketing real world data and
their consistency with their prior clinical trials and to high-
light the limitations and challenges in using these agents in
real world.
Review
Stroke prevention in non-valvular atrial fibrillation
Anticoagulation therapy is necessary to prevent stroke,
systemic embolization and all-cause mortality in patients
with AF. THE CHADS2 score (Cardiac Failure, Hyper-
tension, Age, Diabetes, and Stroke [double]) was widely
used in risk stratification to identify patients who will bene-
fit from anticoagulation [2]. However, even within the score
“0”, the risks of stroke ranged from 0.84 to 3.4 per year,
hence missing out on those with increased risks who would
have benefitted from anticoagulation. This gap was ad-
dressed with the CHA2DS2-VASc score (congestive heart
failure, hypertension, age ≥ 75 years [doubled], diabetes
mellitus, stroke [doubled], vascular disease, age 65–74
years, sex category [female]) which can better identify truly
low risk AF patients, who are unlikely to benefit from anti-
thrombotic therapy [3]. CHASDS2-VASc score is currently
the preferred tool for risk stratification for stroke risk in AF
patients.
Currently 4 DOACs available are dabigatran, rivaroxa-
ban, apixaban and edoxaban have each shown similar ef-
ficacy and safety when compared to warfarin [4–7]. A
meta-analysis of the phase III trials of these four DOACs
showed a consistent favourable risk-benefit profile across a
wide range of patients with significant reductions in stroke
or systemic embolism, intracranial haemorrhage, and mor-
tality but increased gastrointestinal bleeds when compared
with warfarin [8]. Coupled with their convenient usage as
fixed dose oral medications without the need for frequent
laboratory tests and dose adjustments, DOACs have
emerged as the preferred treatment option in some guide-
lines [9]. Large scale real world data of these drugs is has
become available with increasing use of DOACs in routine
care.
Dabigatran, in a review of 9 publications, involving
more than 200,000 AF patients over 5 years [10], showed
that data for dabigatran in ‘real world’ clinical practice
were largely replicative of the main findings in the RE-
LY phase III trial [4]. In particular, both dabigatran doses
at 150 mg and 110 mg twice daily were associated with
lower major extra-cranial bleeding rates than warfarin in
patients less than75 years old and similar event rates in
those above 75 years old. The 110 mg dose was associ-
ated with lower and similar gastrointestinal (GI)
bleeding rates, and the 150 mg dose yielded similar and
higher GI bleeding rates in patients less than 75 years
and more than 75 years old, respectively. A more recent
systematic review and meta-analysis studied 348 750 pa-
tients (56.65 % warfarin, 40.2 % dabigatran-150 mg and
3.2 % dabigatran-110 mg) in routine care and this is 20
times the size of RE-LY patient population [11]. It in-
cluded heterogeneous study cohorts regarding history of
stroke, hypertension, or diabetes mellitus and did not ex-
clude patients with severe renal impairment (creatinine
clearance ≤30 mL/min), active liver disease, or condi-
tions associated with an increased risk of bleeding. Pa-
tients receiving dabigatran-110 mg in routine clinical
practice, tended to be older than patients in the RE-LY trial
on this dose. In pooled analyses, dabigatran-150 mg was
similar to warfarin in preventing stroke (hazard ratio, 0.92;
95 % confidence interval, 0.84–1.01; P = 0.066) and a sig-
nificantly lower risks of intracranial bleeding (0.44; 0.34–
0.59; P < 0.001). However risks of GI bleeding was signifi-
cantly higher than warfarin (1.23; 1.01–1.50; P = 0.041),
particularly in studies of older versus younger populations
(median/mean age, ≥75 versus <75 years; β = 1.53; 95 %
confidence interval, 1.10–2.14; P = 0.020). Again the find-
ings were consistent with the RE-LY trial. Another observa-
tional study provided some insights on the use of
Dabigatran 75 mg dose which was not studied in the RE-
LY trial but approved in the USA for use in the renal im-
paired patients with CrCl 15-30 ml/min [12]. The use of
dabigatran 75 mg was associated with significantly reduced
risk of intracranial haemorrhage and similar rates of stroke,
bleeding and mortality compared to warfarin. Interestingly,
majority of patients on dabigatran 75 mg twice daily ap-
peared not to have severe renal impairment as only 33 %
had a diagnosis of chronic kidney disease, and 20 % of these
with severe renal impairment, thus suggesting a possible
off-label use of the 75 mg dose in many patients in the real
world. While not advocating off label dose reduction, the
observational data are nonetheless reassuring. Other find-
ings noted from such real world observations include the
observations that new starters of warfarin has a higher
bleeding risk when compared to new starters of dabigatran,
warfarin experienced switchers or patients remaining on
warfarin [13], higher bleeding rates in the first 90 days of
treatment in elderly new starters of dabigatran or warfarin
[12, 14] and the higher bleeding risk with renal impairment
regardless of which oral anticoagulant [15–17].
Rivaroxaban, in the Xantus prospective observational
study for 6784 AF patients across 311 centres in Europe
reported a lower thrombotic and bleeding rates for Riv-
aroxaban compared to its Rocket phase III clinical trial
[18]. While the phase III ROCKET AF trial did not in-
clude patients with CHADs score of 0-1, Xantus had
12.7 % of patients had a CHA2DS2-VASc score of either
0 or 1. Generally, patients in Xantus had lower stroke
The Author(s) Thrombosis Journal 2016, 14(Suppl 1):17 Page 134 of 163
risks, with a mean CHADS2 score of 2.0 and 19.0 % ex-
periencing prior stroke/TIA or SE, compared with 3.5
and 55 % respectively in the Rocket AF trial. The overall
bleeding incidence of 2.1 per 100 patient-years in Xantus
was notably lower than 3.6 per 100 patient-years re-
ported in Rocket AF. Similarly fewer major GI bleeds
and ICH were observed in Xantus when compared to
Rocket-AF. Recent analysis from the Dresden Registry
[19] showed the overall rates of stroke and systemic em-
bolism at 2.03/100 patient-years in the intention-to-treat
analysis and 1.7/100 patient-years in the on-treatment
analysis which were considerably lower than those in the
ROCKET AF trial [5]. In addition, event rates for pa-
tients receiving 20 mg OD (1.25/100 patient-years), was
considerably lower than patients on 15 mg OD (2.7/100
patient-years). Bleeding complications associated with
rivaroxaban was addressed in a meta-analysis of 9 stud-
ies involving 51,533 patients in real world [20]. It
showed the mean pooled rates of any major bleeding,
major GI bleeding or ICH with rivaroxaban were 3.32,
(95 % CI¼2.28–4.25); 2.41, (95 % CI¼1.25–3.56) and
0.40, (95 % CI¼0.17–0.74) events/100 patient-years. The
pooled real-world rates of these bleeding rates largely mir-
rored those reported for rivaroxaban in the phase 3
ROCKET AF trial [5]. However, there were significant
variability and heterogeneity variability in major bleeding
rates across the studies. Five studies were retrospective
claims analyses and identified bleeding using International
Classification of Diseases–9/10 codes, while four were
prospective registry studies and identified bleeding clinic-
ally using the International Society on Thrombosis and
Haemostasis (ISTH) definition. Major bleeding rates and
major GI bleeding rates as per 100 patient-years in studies
that relied on claims were (2.86 to 12.79) and (2.53 to 9.5)
respectively and these are substantially higher than (0.96
to 3) and (0.19 to 0.9) as reported in prospective studies
using clinical identification. Such differences underscore
the substantial heterogeneity across the studies and the in-
herent weaknesses associated with retrospective and ob-
servational studies. Nonetheless, the pooled rates of major
bleeding with rivaroxaban estimated were generally low
and consistent with those reported in ROCKET AF. This
finding of a lower major bleed rate than Rocket AF was
also seen in a large US study of electronic medical records
of 27 467 patients (2.9 events per 100 patient-years) [18]
as well as an earlier report from Dresden NOAC Registry
involving 1200 AF patients treated with rivaroxaban(3.1
events per 100 patient-years) [21, 22].
Besides these published large scale real world compari-
sons of a single DOAC versus warfarin, evidence relating
to the overall effectiveness and safety of all oral anti-
coagulant drugs used in clinical practice is emerging. An
observational nationwide cohort study in Denmark had
involved 61, 678 patients with non-valvular AF who
were naïve to oral anticoagulants and had no previous
indication for valvular AF or VTE [23]. The study popu-
lation was distributed according to treatment type with
57 % warfarin, 21 % dabigatran 150 mg, 20 % on rivarox-
aban 20 mg, and 10 % apixaban 5 mg. The baseline char-
acteristics of patients in apixaban and rivaroxaban has
more previous strokes, systemic embolism vascular dis-
ease and bleeding while dabigatran patients were youn-
ger and less renal impaired, warfarin has more patients
with vascular disease hypertension, renal impairment,
COPD and cancer. During 1 year follow-up, when com-
pared to warfarin, annual rates of ischaemia strokes and
systemic embolism were significantly lower for rivaroxa-
ban (hazard ratio 0.83 (95 % confidence interval 0.69 to
0.99), while not significantly different for dabigatran and
apixaban.(hazard ratios of 2.8 % and 4.9 % respectively)
The mortality risk was significantly lower with apixaban
(5.2 %) and dabigatran (2.75 %) when compared with war-
farin (8.5 %), but not with rivaroxaban (7.7 %). No signifi-
cant difference was found between DOACs and warfarin
for ischaemic stroke. The bleeding endpoints for rivaroxa-
ban 5.3 % was comparable to warfarin 5 %, while apixaban
2.3 % and dabigatran 2.4 % were both lower than warfarin.
The risks of death, any bleeding, or major bleeding were
significantly lower for apixaban and dabigatran compared
with warfarin. This real world study concluded that all
three DOACs seem to be safe and effective alternatives to
warfarin in a routine care setting.
Real-life studies have their inherent weaknesses such as
non-controlled and heterogeneous patient groups, uncon-
trolled influence of non-compliance, other concomitant
medications and co-morbidities. However, they provide a
wealth of data and insight into how DOACs are used in
the real world. Despite the reassuring real world data on
use of DOACs in routine care, the benefits of DOACs are
not applicable to all patients. As shown in a smaller scale
study involving 468 patient with AF from the UZ Brussel
Stroke Registry, it was found that less than half of real life
patients are eligible for therapy with one of the DOACs
[24]. Reasons for non-eligibility include concomitant use
of antiplatelet agents with apixaban, impaired renal func-
tion in dabigatran, concomitant use of rifampicin and
anti-fungal drugs and presence of valvular heart diseases.
More data are also required for AF patients on DOACs
undergoing cardioversion or ablation. There are ongoing
trials addressing some of these issues and their results to-
gether with more real world data can add more clarity to
these limitations.
DOACs in Asia for AF patients
AF with its risks for ischaemic stroke is expected to pose
a huge health burden in Asia. Although the DOACs are
emerging as the preferred class of anticoagulant for
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stroke prevention in AF, there are concerns if the results
of their global clinical trials are applicable to Asians. Sub-
groups analysis of more than 8000 Asian patients was per-
formed in a meta-analysis of 5 pivotal phase III trials for
the four available DOACs, namely RE-LY, ROCKET AF, J-
ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48
[25]. The results showed greater benefits of DOACs in
Asians with a greater reduction in stroke and systemic em-
boli when compared to non-Asians. As for bleeding com-
plications, Asians also fared better with fewer bleeds than
non-Asians. This is despite Asian patients on the warfarin
comparator arm having less optimal time in therapeutic
range, with more having international normalized ratio
<2.0 and fewer had international normalized ratio >3.0. In
particular, bleeding from the gastrointestinal track was
similar between Asians on DOACs and vitamin K antago-
nists, but increased in non-Asians who were on DOACs.
In studying the differences between Asians and non-
Asians individually in each of the four DOACs [26], the
relative risk reduction in stroke and systemic embolization,
hemorrhagic stroke as well as all-cause mortality showed a
greater numerical reduction in Asians compared to non-
Asians for Dabigatran at 150 mg, 110 mg, Rivaroxaban
20 mg, Apixaban 5 mg and Edoxaban 60 mg. There was
no evidence of increased risk of GI bleeding associated
with DOACs in Asians. Hence it is expected that DOACs
will become the preferred class of anticoagulant in the
stroke prevention for AF in Asians.
In the real world, data the Taiwan National Health In-
surance Research Database with close to 10,000 AF pa-
tients on each arm of treatment with either warfarin or
dabigatran, has shown that Dabigatran significantly re-
duced risk of ischemic stroke, ICH, all hospitalized
major bleeding and all-cause mortality compared with
warfarin [27]. Rates of major GI bleeding and myocardial
infarction were not increased in dabigatran when com-
pared with warfarin. A multicenter retrospective cohort
study of 241 stroke centers in Japan, patients with AF
treated with a DOAC when compared with those on
warfarin, had a lower rates of intracranial haemorrhage
(17 % vs 26 %) and mortality (16 % vs 35 %) [28]. Such
real world reports further bolster the confidence in the
safety and efficacy of DOACs treatment for AF patients
in Asia.
Thrombo-prophylaxis in major orthopaedic surgeries
In the phase III clinical trials for thromboprophylaxis in
major orthopaedic surgeries, rivaroxaban, dabigatran
and apixaban were found to be effective and safe without
a significant increase in bleeding complications when
compared to enoxaparin 40 mg once daily [25] and edoxa-
ban was found to be more effective when compared with
enoxaparin 20 mg once daily [29–31]. With early
discharge after surgery, the DOACs make a very attractive
option for continued prophylaxis after hospital discharge.
In an observational study in routine practice using dabi-
gatran for thrombo-prophylaxis in 5292 hip and knee re-
placement surgeries [32], for patients with pre-specified
age, renal function and body mass index (BMI), the com-
posite incidence of symptomatic VTE events and all-cause
mortality was 1.04 % (95 % CI 0.78, 1.35) and the post hoc
analysis incidence of major bleeding events to be consist-
ent with the findings in clinical trials, thus providing re-
assurance with regards to efficacy and safety of its use in
routine practice. A three-fold increase in symptomatic
VTE and all-cause mortality was seen in patients with
moderate renal impairment of creatinine clearance of 30–
49/ml who received dabigatran and a 2 fold increase in
major bleeding was seen in the severely obese patients
with BMI above 35 kg/m2. High level of satisfaction with
dabigatran use was also reported despite the difficult and
time consuming process of implementing dabigatran into
routine practice [33].
Rivaroxaban in routine care for thromboprophylaxis
post major orthopaedic surgery was similarly evaluated.
XAMOS, a phase IV, non-interventional study in 17,701
patients across 37 countries showed that the incidence
of symptomatic thromboembolic events was significantly
lower in patients who received rivaroxaban compared
with standard of care (0.9 % vs 1.4 %) [34] Treatment re-
lated major bleeding events as defined in the RECORD
programme were similar between the rivaroxaban and
standard of care groups at 0.4 % and 0.3 %, respectively.
However, non-major bleeding and any bleeding rates
were higher in the rivaroxaban group compared with the
standard of care group (2.9 % vs 1.7 %, and 4.7 % vs
3.2 %, respectively). Nonetheless the overall data from
XAMOS confirmed the favourable benefit–risk profile of
rivaroxaban when used in routine clinical care. From the
ORTHO-TEP registry of about 5000 patients in a single
centre, rivaroxaban vs fondaparinus or low molecular
weight heparin was retrospectively evaluated for the pre-
vention of VTE [35, 36]. The rivaroxaban group demon-
strated a significant reduction in symptomatic VTE and a
numerical reduction in pulmonary embolism. Significant
reduction in major bleeding rates, number of surgical revi-
sions due to bleeding complications, blood transfusion
rates and length of hospital stay were also seen in the riv-
aroxaban group. Notwithstanding the inherent bias and
inadequacies in retrospective study designs, ORTHO-TEP
confirmed that the efficacy of rivaroxaban was at least not
offset by any increase in surgical complications.
Treatment of acute VTE
Similar to stroke prevention in patients with non-valvular
AF, the DOACs have demonstrated excellent efficacy and
safety in large scale phase III trials in the treatment of VTE
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[37–41]. Evidence from real life studies are pending from
ongoing studies such as : (i) Dresden Noac Registry (clini-
caltrials.gov identifier: NCT01588119), (ii) XALIA study
which is a non-interventional observational cohort study
investigating rivaroxaban in VTE treatment in routine clin-
ical practice (clinicaltrials. gov identifier: NCT01619007),
(iii) PREFER in VTE, a multicentre, prospective observa-
tional disease registry for quality of life and treatment satis-
faction for 4000 patients with VTE across Europe [42] and
(iv) The GARFIELD-VTE registry, an observational study
for about 10,000 patients to look at the acute and long
term management of VTE, its complications and health-
care resource utilization.
The use of DOACs in the treatment of VTE associated
with Antiphospholipid requires more clarity as this con-
dition is associated with much increased risks for recur-
rences. A prospective phase II/III clinical trial using
Rivaroxaban in antiphospholipid syndrome is currently
in progress to address these efficacy and safety issues
[43]. Cancer associated VTE represents a good propor-
tion of VTE patients for which low molecular weight
treatment is regarded as the gold standard. While these
patients are at higher risks of recurrence and bleeding,
they may also be on medications which may interact with
DOACs via the CYP3A4 and P-gp metabolic pathways.
The main limitation in using DOACs is the lack of efficacy
and safety data from clinical trials specific for use of
DOACs in the treatment of cancer associated VTE. Al-
though subgroup analysis of cancer patients from meta-
analysis of the major clinical trials for DOACs in the treat-
ment of VTE showed similar efficacy and safety when
compared to warfarin, it is not clear if these cancer pa-
tients had active cancer, what were the risks of bleeding
and recurrence specific to their cancer types and whether
they are on cancer treatment with potential drug inter-
action with DOACs [44].
Real life management issues
While it is reassuring that the body of emerging “real
world data” from the routine use of NOACs largely mir-
rors that in clinical trials, there remains many concerns
on the limitations of this new armamentarium for better
management of thrombotic diseases.
Appropriate choice of anticoagulant and patient care
when using DOACs
Choosing a particular DOAC for a patient can be diffi-
cult as not all DOACs are the same [45]. There is no evi-
dence to recommend one agent over another because
the DOACs have never been compared in head-to-head
trials. Hence the guiding principle has been to match the
right drug to the right patient based on the dosing prop-
erties of each drug, the efficacy and safety and side effect
profile as demonstrated in phase III trials and real world
data, as well as the compliance, affordability and accessi-
bility of the DOACs. Therefore understanding the prop-
erties of the drugs is fundamental to ensure safe and
appropriate prescribing practice (Table 1). All DOACs
depend variably on renal excretion; they are contraindi-
cated in renal failure and should be used with caution
with dose reductions in the renal impaired patients. The
relative lack of drug interactions in DOACs is an advan-
tage but clinicians must be mindful of the few important
drug interactions with some anti-fungal, anti-microbial
and anti-viral medications involving the CYP3A4 and P-
gp metabolic pathways. The dosing regimen and dose
adjustments for renal impairment are DOAC specific
and different from each other and thus predispose to
dosing and prescription errors if clinicians are not famil-
iar with these anticoagulants. There are also clinical situ-
ations where DOACs are not suitable because of
insufficient data on its efficacy and safety such as
thromboembolism associated with anti-phospholipid syn-
drome and the unstable cancer patient, or where there are
safety concerns as during pregnancy and for patient with
mechanical heart valves. The notion of a simplified coagu-
lation treatment approach is actually more complicated
than anticipated and guidelines such as the NICE guide-
lines (https://www.nice.org.uk/guidance/cg180/resources/
nic-consensus-statement-on-the-use-of-noacs-243733501)
and the EHRA practical guide [46] are useful resources for
clinicians prescribing DOACs. In situations when transit-
ing between DOACs and other anticoagulants and during
the peri-operative periods, due caution should be exercised
taking into consideration the patient’s renal function and
the half-life of the DOAC for appropriate drug dosing and
time of administration. To minimise the bleeding risks,
these agents should be used in the appropriate patients
and managed well when transiting between DOAC and
other anticoagulants and during the peri-operative periods
[46].
Laboratory coagulation tests
Patients on DOACs do not need routine coagulation
monitoring. However, there are certain clinical scenarios
in which coagulation testing and measurement of drug
levels are necessary, such as episodes of bleeding, peri-
operative management, suspected over dosage either from
drug interactions or intentional overdose, renal impair-
ment or a measure of suspected non-compliance. The ef-
fects of DOACs on routinely available clot-based tests
such as APTT, PT and TT are variable and the degree of
prolongation is highly dependent on the reagent used for
the assay [47]. These widely available tests may be used to
detect peak or supra-therapeutic drug levels, but should
not be used for quantitation. Such routine coagulation
tests may also appear normal during trough drug levels. In
situations where drug levels are required and these are
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measured with specialized tests [48]. Dabigatran can be
measured by the dilute thrombin time, ecarin assay and
chromogenic anti-IIa assay. The anti-Xa DOACs can be
measured by STA Neoplastin test and the anti-Xa assays.
Unfortunately, such specialised laboratory facilities are not
widely available, except in major hospitals, and very often
not available when required.
In addition to influencing the results of clotting times,
DOACs may also cause potential errors in some special-
ized coagulation tests, particularly, the clot based assays
[49]. DOACs can falsely prolong the dilute Russels Vi-
pers Venom Time (dRVVT) in lupus anticoagulant tests,
falsely reduced levels of plasma clotting factors in one
staged assays and falsely elevate the functional protein S
levels. Generally, clinicians may not appreciate the im-
pact of DOACs on coagulation tests, hence guidance
from the local laboratory is important for appropriate re-
quests, timing and interpretation of these tests for pa-
tients on DOAC treatment [50].
Management of DOAC associated bleeding
All anticoagulants, including the DOACs are associated
with bleeding. Unlike warfarin and heparins where
established reversal protocols with known antidotes are
readily available for managing bleeds, clinicians may not
be equipped with the bleeding management and reversal
strategies in DOACs [51]. It is imperative that clinicians
be equipped to manage bleeds by means of a local man-
agement plan stratified according to the severity of
bleeds and availability of treatment agents [52] Exact
identification of which DOAC, location and severity of
bleeds, renal function and the time of last ingestion of
DOAC are important factors to note in the management
of bleeding associated with DOACs.
For mild bleeding events such as bruises or menorrhagia,
the DOAC could be suspended and the drug restarted later
at a lower dose and resuming full dose when bleed risks
had resolved. For moderate to severe bleeds, symptomatic
treatment such as mechanical compression of bleeding site,
appropriate surgical or radiological intervention and blood
transfusion may be necessary. Plasma and cryoprecipitate
do not reverse the anticoagulant effect of novel agents, but
may be required for correction of volume loss or coagulop-
athy associated with other co-morbidities. Adsorption of
remnant DOACs by oral activated charcoal may be helpful
if the last ingested dose of is within 2 h at presentation to
the hospital [53]. Haemodialysis, with its logistic challenges,
can be considered for removal of residual dabigatran [54]
but not for the anti-Xa inhibitors like rivaroxaban or
apixaban.
In the events of life threatening bleeds, off label use of
pharmacological haemostatic agents such as prothrombin
concentration complex and recombinant factor VIIa can
be considered. However, such measures are controversial
and without good supportive evidence [55]. Clinical devel-
opment for specific antidotes to the DOACs took place
only after DOACs reached routine use. The humanized
monoclonal Fab BI 655075 or Idarucizumab specific for
reversal of the anticoagulant effects of dabigatran has
completed its phase III trial [56]. It has now been regis-
tered for use in many countries. Andexanet alfa [57], a
FXa inhibitor antidote, is in advanced stages of clinical
trial development. It is a recombinant modified human
factor Xa decoy protein that is catalytically inactive but
binds factor Xa inhibitors in the active site with high affin-
ity, hence restoring the activity of endogenous factor Xa
and reducing levels of anticoagulant activity. The availabil-
ity of specific antidotes for the DOACs will certainly pro-
vide a better sense of security into their routine use.
However, it is prudent to highlight the appropriate use of
such antidotes [58]. Reasonable indications include life
threatening and critical organ bleeds, bleeding that did
not respond to conventional supportive and hemostatic
measures, and for urgent surgical and invasive interven-
tions with high risks of bleed that cannot be delayed. In
the decision to reverse anticoagulation completely, one
must take into consideration the pro-thrombotic risks that
the patient has which required anticoagulation in the first
place, hence such reversal should be taken lightly for triv-
ial reasons just because reversal agents are available.
Table 1 Pharmacological properties of the DOACs
Dabigatran [9, 38] Rivaroxaban [9, 40, 41] Apixaban [9, 37] Edoxaban [9, 39]
Target Factor IIa Factor Xa Factor Xa Factor Xa
Half-life (hour) 12-17 5-9 12 6-10
Time to peak effect (hour) 1-3 2-4 1-3 1-2
Renal clearance as unchanged drug (%) 80 33 27 50
Drug Interactions Pathways P-gp 3A4/P-gp 3A4/P-gp 3A4/P-gp
Dosing in non-valvular AF 150 mg BID 20 mg OD 5 mg BID 60 mg OD
Dosing in VTE treatment 150 mg BID after 5-10 days of
parenteral anticoagulation
15 mg BID for 21 days
followed by 20 mg OD
10 mg BID for 7 days
followed by 5 mg BID
60 mg OD after 5 days of
parenteral anticoagulation
OD-once daily, BID-twice daily, P-gp – P-glycoprotein, 3A4 – cytochrome P450 3A4 isoenzyme
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Cost effectiveness of DOACs
Affordability and accessibility for DOACs remains an
issue in Asia. While some studies have advocated the
positive cost savings and cost-effectiveness of DOACs in
routine clinical practices [59–61], these may not be ap-
plicable to many countries with different healthcare sys-
tems. Also, the cost effectiveness as calculated from
healthcare providers’ perspective may not be portable to
the full paying individual without subsidized healthcare
benefits [62].
Conclusion
DOACs represent an important advancement in anti-
thrombotic management. Real world data consistent
with their clinical trial data is reassuring. However, a sig-
nificant number of patients may not be eligible for treat-
ment with a DOAC from a lack of data in conditions
not addressed in their clinical trials. In addition, costs of
these medications may limit their accessibility to a good
number of patients. In routine clinical care, much has to
be done to familiarize the clinicians on the use of these
drugs. It is the careful patient selection, appropriate
management and the ability to prevent and manage the
bleeding complications that will permit optimization on
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